Andrew is a Partner at Hogan Lovells. He is an experienced trusted advisor and counsel to global life sciences, pharmaceutical, and emerging technology clients on matters involving corporate formation, public and private financing, mergers and acquisitions, cross-border licensing and joint ventures, employment and executive compensation, and intellectual property. Andrew represents public and private life sciences, pharmaceutical, and emerging technology companies as well as public and private academic and research institutions on a variety of diverse matters.
That’s where it all begins. Most research that results in drug discovery generally starts at universities.
FUJIFILM Dyosynth Biotechnologies, Taysha Gene Therapies, Veravas highlight innovation stemming from the Lone Star state. BioSpace takes a deep dive into these and other Texas innovators.